Kit for judging pathological state of Rater's syndrome and application of gene contained in mitochondrial genome as biomarker

By detecting genes with unmethylated CpG motifs in the mitochondrial genome, using PCR technology, a Rett Syndrome pathological status determination kit is provided, which solves the problem of difficult to easily evaluate the pathological status of RTT in the prior art, and realizes biological-based Simple diagnosis of markers.

CN119095986APending Publication Date: 2024-12-06INST OF RHEOLOGICAL FUNCTION OF FOOD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036223.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-06
Filing Date
2023-05-01
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to easily evaluate the progress and recovery of pathological status of Rett syndrome (RTT), and mainly relies on behavioral observation and lack of effective biomarkers for diagnosis.

Method used

By detecting the genes contained in the mitochondrial genome as ligands of TLR9, using polymerase chain reaction (PCR) technology to amplify and quantitatively analyze the relevant gene sequences, provide the Retel Syndrome pathological status determination kit, and use the non-arrhea in the mitochondrial genome The synthesized CpG motif serves as a biomarker.

Benefits of technology

The pathological status of Rett syndrome is achieved to easily determine the pathological status progression by changing the abundance of mitochondrial genomic genes in blood and other samples, providing a basis for auxiliary diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095986A_ABST
    Figure CN119095986A_ABST
Patent Text Reader

Abstract

The invention provides a kit for judging the pathological state of the Rater's syndrome. The kit comprises a reagent for detecting genes contained in a mitochondrial genome in a sample collected from an object.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a Rett syndrome pathological state determination kit and use of genes contained in mitochondrial genome as biomarkers. Background Art

[0002] Rett syndrome (hereinafter referred to as "RTT") is a progressive neurodevelopmental disorder caused by a mutation in the MeCP2 gene located on chromosome X. RTT mainly occurs in girls who grow normally about six months to one year after birth, but then show various neurological symptoms such as autism tendencies.

[0003] Toll-like receptor (TLR) 9 is known to be associated with brain inflammation in RTT model mice lacking the MeCP2 gene (see non-patent document 1). TLR mainly induces Th1 against microbial infection and participates in natural immunity together with NK cells, etc. TLR9 is known to recognize unmethylated CpG motifs of viral DNA and bacterial DNA. Non-patent document 2 reports that MeCP2 gene mutations lead to decreased mitochondrial function and impaired mitochondrial function in RTT.

[0004] Prior art literature

[0005] Non-patent literature

[0006] Non-patent document 1: Nakajima Hideyuki, "2019 Research Grant Report: Elucidation of the pathogenesis of Rett syndrome caused by microglial activation via endogenous ligands and development of treatment methods", [Online], June 1, 2020, NPO Rett Syndrome Support Organization, [retrieved on April 22, 2020], Internet link<URL:https: / / www.npo-rett.jp / rett_img / rett_zyosei_p / nakashima_hokoku.pdf>

[0007] Non-patent document 2: Natalya Shulyakova et al., "Mitochondrial Dysfunction in the Pathogenesis of Rett Syndrome: Implications for Mitochondria-TargetedTherapies", Frontiers in cellular neuroscience, 2017, 11, 58

[0008] Non-patent document 3: Aoki no Meku et al., “Revised Diagnostic Criteria for Rett Syndrome (2010 Edition)”, Rett Syndrome Diagnostic Guidelines, Osaka University Press, March 23, 2015, pp. 21-23 Summary of the invention

[0009] Technical issues to be solved

[0010] The diagnostic requirements for RTT are the presence of degeneration and the fulfillment of all major diagnostic criteria and exclusion criteria. The main diagnostic criteria are the presence or absence of loss of hand function, voice and language communication, gait abnormality, and stereotyped hand movements (see non-patent document 3). As mentioned above, the diagnosis of RTT is mainly based on behavioral observations. In order to easily evaluate the progression of the pathological state of RTT and the recovery of the pathological state, biomarkers related to the pathological state of RTT are needed.

[0011] The present invention has been made in view of the above circumstances, and its object is to provide a Rett syndrome pathological state determination kit capable of simply determining the Rett syndrome pathological state and the use of genes contained in the mitochondrial genome as biomarkers.

[0012] Solutions to the problem

[0013] The present inventors focused on the fact that the CpG motifs of the mitochondrial genome are hardly modified by methylation, and conducted intensive studies based on the assumption that genes or fragments contained in the mitochondrial genome function as ligands for TLR9. As a result, they obtained the knowledge that more genes contained in the mitochondrial genome can be detected in blood or the like by inhibiting or knocking out the expression of MeCP2, thereby completing the present invention.

[0014] The Rett syndrome pathological state determination kit according to the first aspect of the present invention includes a reagent for detecting a gene contained in a mitochondrial genome in a sample collected from a subject.

[0015] The reagents may be primers for amplifying at least a portion of the base sequence of the gene as a template in a polymerase chain reaction, and probes that hybridize with at least a portion of the base sequence of an amplification product amplified by the polymerase chain reaction.

[0016] The above-mentioned Rett syndrome pathological state determination kit according to the first aspect of the present invention may further include a labeling substance that indicates hybridization between the probe and the base sequence of the amplification product.

[0017] The gene can be selected from the group consisting of a gene encoding 16S ribosomal RNA, a gene encoding cytochrome c oxidase subunit 1, a gene encoding cytochrome c oxidase subunit 2, a gene encoding cytochrome c oxidase subunit 3, a gene encoding cytochrome b, a gene encoding NADH dehydrogenase 1, a gene encoding NADH dehydrogenase 2, a gene encoding NADH dehydrogenase 3, a gene encoding NADH dehydrogenase 4, a gene encoding NADH dehydrogenase 4L, a gene encoding NADH dehydrogenase 5, a gene encoding NADH dehydrogenase 6, a gene encoding ATP synthase 6, and a gene encoding ATP synthase 8.

[0018] The use according to the second aspect of the present invention is the use of genes contained in the mitochondrial genome as biomarkers for assisting in determining the pathological state of Rett syndrome in a subject.

[0019] Effects of the Invention

[0020] According to the present invention, the pathological state of Rett syndrome can be easily determined. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The graph shows the relative abundance of a gene encoding 16S ribosomal RNA (16S) and a gene encoding cytochrome c oxidase subunit 1 (CO1) in a culture medium in which cells in which MeCP2 expression was suppressed by shRNA were cultured.

[0022] Figure 2 It is a graph showing the relative abundance of 16S and CO1 in the serum of MeCP2 knockout mice as an RTT model.

[0023] Figure 3 The diagrams show the relative abundance of each gene contained in the mitochondrial genome in the plasma of MeCP2 knockout mice. (A), (B), (C), (D), (E), (F), (G), and (H) are diagrams showing the relative abundance of 16S, CO1, a gene encoding cytochrome c oxidase subunit 2 (CO2), a gene encoding cytochrome b (CYTB), a gene encoding NADH dehydrogenase 1 (ND1), a gene encoding NADH dehydrogenase 2 (ND2), a gene encoding NADH dehydrogenase 3 (ND3), and a gene encoding ATP synthase 6 (ATP6), respectively.

[0024] Figure 4The graphs show the relative abundance of each gene contained in the mitochondrial genome in the plasma of MeCP2 knockout mice. (A), (B), (C), (D), (E), and (F) are graphs showing the relative abundance of the gene encoding ATP synthase 8 (ATP8), the gene encoding cytochrome c oxidase subunit 3 (CO3), the gene encoding NADH dehydrogenase 4L (ND4L), the gene encoding NADH dehydrogenase 4 (ND4), the gene encoding NADH dehydrogenase 5 (ND5), and the gene encoding NADH dehydrogenase 6 (ND6), respectively. DETAILED DESCRIPTION

[0025] Embodiments according to the present invention are described with reference to the accompanying drawings. In addition, the present invention is not limited to the following embodiments and the accompanying drawings. In addition, in the following embodiments, expressions such as "having", "including" or "containing" also include the meaning of "consisting of" or "composed of".

[0026] (Implementation Method 1)

[0027] The RTT pathological state determination kit according to the present embodiment includes a reagent for detecting the genes contained in the mitochondrial genome. Mitochondria are intracellular organs of eukaryotic cells. Mitochondria are organs that produce energy by oxidative phosphorylation. There are multiple mitochondria in the cell, and the mitochondria themselves have multiple mitochondrial genomes (also referred to as "mitochondrial DNA"). Therefore, the cell has multiple mitochondrial genomes, and each mitochondrial genome is not necessarily the same.

[0028] It is believed that since MeCP2 gene mutation leads to decreased mitochondrial function and mitochondrial function is impaired in RTT, DNA with unmethylated CpG motifs derived from the mitochondrial genome binds to TLR9, thereby inducing brain inflammation. In other words, genes contained in the mitochondrial genome are indicators of the pathological state of RTT.

[0029] The gene to be detected may be any gene as long as it is contained in the mitochondrial genome, and examples of such genes include genes encoding 12S ribosomal RNA, 16S, CO1, CO2, CO3, CYTB, ND1, ND2, ND3, ND4, ND4L, ND5, ND6, ATP6, ATP8, and genes encoding 22 types of tRNA.

[0030] The reagent according to this embodiment detects the above-mentioned gene in a sample collected from a subject. The subject is specifically a human. Preferably, the subject is a human suspected of having RTT or an RTT patient. The sample is any biological sample, such as the subject's blood, serum, bone marrow fluid, saliva, semen, peritoneal fluid, urine and other body fluids, liver and skin cells, etc. The DNA contained in the sample can be extracted and purified by a known method.

[0031] Preferably, the reagent includes primers for amplifying at least a portion of the base sequence of the above-mentioned gene as a template in a polymerase chain reaction (PCR), and a probe hybridized with at least a portion of the base sequence of the amplified product amplified by PCR. Preferably, at least a portion of the base sequence of the gene is a unique base sequence that only has the gene and does not have other genes. The primers used in PCR are designed to amplify, for example, a nucleic acid of a continuous base sequence of at least 10 bases or more of the above-mentioned gene, a nucleic acid of a base sequence of preferably 50 bases to 200 bases, a nucleic acid of a base sequence of more preferably 100 bases to 150 bases, and at least one of nucleic acids complementary to them.

[0032] The amplification product is detected or quantified using a probe that hybridizes with at least a portion of the base sequence of the amplification product. The probe refers to a nucleic acid fragment used to analyze a specific portion of a nucleic acid or its base sequence by hybridization based on nucleic acid complementarity. The probe is, for example, an oligonucleotide that hybridizes with a continuous base sequence of at least 10 bases of the amplification product, preferably a base sequence of 10 to 100 bases, more preferably a base sequence of 10 to 50 bases, or a base sequence complementary to these base sequences.

[0033] Although the base sequence of the probe hybridizes with the amplified product, it may not be completely complementary to the base sequence of the amplified product, as long as it does not hybridize with nucleic acids other than the amplified product, and may include one or more substituted, deleted or added base sequences in the base sequence that is completely complementary to the base sequence of the amplified product.

[0034] In order to quantitatively detect the above-mentioned genes contained in the mitochondrial genome, the RTT pathological state determination kit according to the present embodiment preferably also includes a labeling substance representing the hybridization of the base sequence of the probe and the amplification product. For example, as the labeling substance, fluorescent dyes and radioactive substances can be cited, but the labeling substance is preferably used for quantitatively measuring the amplification product amplified in PCR. The amplification product can be quantified by known methods such as the intercalation method, hybridization method and LUX method via a fluorescent dye. The intercalation method uses a fluorescent dye that specifically inserts into double-stranded DNA and emits fluorescence. The hybridization method uses a probe modified with a fluorescent dye.

[0035] The hybridization conditions are stringent conditions, that is, the probe hybridizes with the amplification product but does not hybridize with nucleic acids other than the amplification product. Stringent conditions can be appropriately determined based on, for example, Molecular cloning a laboratory manual, 3rd edition (2001). Stringent conditions are, for example, 0.2×SSC, 0.1% SDS, and incubation at 65°C.

[0036] Next, a method of using the RTT pathological state determination kit according to the present embodiment is described. First, the above reagent is used to detect genes included in the mitochondrial genome in a sample collected from a subject.

[0037] When the probe is hybridized with the amplification product via a labeled substance detection probe, the amount of amplification product produced can be determined by measuring the signal of the labeled substance. The amount of amplification product produced is related to the abundance of the above-mentioned gene contained in the mitochondrial genome contained in the sample. Therefore, the RTT pathological state of the object can be determined based on the amount of amplification product produced. In the determination of the pathological state, for example, a pre-set reference value and a measured value are compared. As a reference value, an average value of the measured values ​​of objects that are not RTT can be used. In addition, the degree of progression of the RTT pathological state is defined, the average value of the object measured values ​​corresponding to each degree of progression is calculated in advance, and the reference value determined for each degree of progression is compared with the measured value of the pathological state determination object, so that the degree of progression of the pathological state of the pathological state determination object can be determined.

[0038] According to the RTT pathological state determination kit of the present embodiment, the RTT pathological state of a subject can be determined by detecting genes included in the mitochondrial genome in a sample collected from the subject, and thus the method is simple and convenient.

[0039] As described above, the presence or abundance of genes contained in the mitochondrial genome in the sample collected from the subject becomes useful information for determining the pathological state of Rett syndrome. Therefore, in another embodiment, the use of genes contained in the mitochondrial genome as biomarkers for assisting the determination of the pathological state of Rett syndrome in the subject is provided. In addition, in another embodiment, a method for determining the pathological state of RTT is provided. The method for determining the pathological state of RTT includes: a quantification step, using the above-mentioned reagent to quantify the genes contained in the mitochondrial genome in the sample collected from the subject; and a determination step, determining the RTT pathological state of the subject based on the amount of the gene. In addition, a method for treating RTT is provided, including: a quantification step; a determination step; and an administration step, administering an RTT therapeutic drug to the subject based on the RTT pathological state determined in the determination step.

[0040] Example

[0041] The present invention will be described in more detail below with reference to the following examples, but the present invention is not limited to these examples.

[0042] Test Example 1

[0043] [Establishment of shRNA-expressing cell lines]

[0044] The vector expressing shRNA targeting mouse MeCP2 (NM_010788) (Product No.: TRCN0000304464, manufactured by Sigma) is used as "shMeCP2". A PCR amplification product is obtained for shMeCP2, and a vector is prepared to remove the MeCP2 target sequence, which is referred to as "shCont." The base sequences of the forward primer and reverse primer used in PCR for shMeCP2 are shown as SEQ ID NO.1 and SEQ ID NO.2, respectively.

[0045] The shMeCP2 or shCont. gene was introduced into mouse glial cell-derived BV2 cells cultured in DMEM (Sigma) containing 10% fetal calf serum (FCS, Sigma), and puromycin-resistant strains (puromycin concentration was 1 μg / ml) were isolated using the puromycin resistance gene contained in the vector. The obtained cells were designated as BV2 / shMeCP2 and BV2 / shCont.

[0046] [Recovery of genomes from the culture medium of shRNA-expressing cell lines and quantification of genes contained in the mitochondrial genome]

[0047] The culture medium of BV2 / shMeCP2 and BV2 / shCont. was recovered, and the genome was recovered from the supernatant obtained by centrifugation at 1000×g for 5 minutes using DNeasy Blood&Tissue Kit (manufactured by QIAGEN). Next, real-time PCR was performed using SYBR Premix Ex Taq (trademark) II (Tli RNase H Plus) (manufactured by TAKARA BIO Co., Ltd.) and ABI7500 Real Time System (manufactured by Applied Biosystem). In real-time PCR, the hexokinase 2 gene (HK2) contained in nuclear DNA and 16S and CO1 contained in the mitochondrial genome were quantified. The base sequences of the forward primer and reverse primer for HK2 used in real-time PCR are shown as SEQ ID NO.3 and SEQ ID NO.4, respectively. The base sequences of the forward primer and reverse primer for 16S used in real-time PCR are shown as SEQ ID NO.5 and SEQ ID NO.6, respectively. The base sequences of the forward primer and the reverse primer for CO1 used in real-time PCR are shown as SEQ ID NO. 7 and SEQ ID NO. 8, respectively.

[0048] (result)

[0049] Figure 1The relative abundance of 16S and CO1 in BV2 / shMeCP2 and BV2 / shCont. medium normalized by HK2 abundance is shown. The abundance of 16S and CO1 was increased by inhibiting MeCP2 expression.

[0050] Test Example 2

[0051] [Recovery of genomes from MeCP2 knockout (MeCP2-KO) mouse serum and quantification of genes contained in the mitochondrial genome]

[0052] Heart blood was collected from 8-week-old male wild-type mice (WT) and 7-week-old MeCP2-KO mice 003890 (B6.129P2(C)-Mecp2tm1.1Bird / J, The Jackson Laboratory) as RTT model mice under pentobarbital anesthesia (injection of 0.1-0.2 ml). The blood was allowed to stand on ice for 30 minutes, then centrifuged at 3000 rpm for 10 minutes at 4°C, and the serum component of the supernatant was recovered. Next, the genome was recovered from 50 μl of serum using the DNeasy Blood&Tissue Kit (manufactured by QIAGEN). For the recovered genome, real-time PCR was performed in the same manner as in Experiment 1 above, and 16S and CO1 in the serum of each mouse were quantified.

[0053] (result)

[0054] Figure 2 The relative abundance of 16S and CO1 in WT and MeCP2-KO sera normalized by HK2 abundance is shown. In MeCP2-KO, the abundance of 16S and CO1 is high.

[0055] Test Example 3

[0056] [Recovery of genomes and quantification of mitochondrial genomes in plasma of MeCP2-KO mice]

[0057] From 4-week-old male WT and MeCP2-KO mice 003890, heart blood was collected using a 1 ml syringe injected with 5000 units / 5 ml sodium heparin under pentobarbital anesthesia (injection of 0.1-0.2 ml). The blood was allowed to stand on ice for 30 minutes, then centrifuged at 3000 rpm for 30 minutes at 4°C, and the serum component of the supernatant was recovered. Next, the genome was recovered from 50 μl of serum using the DNeasy Blood & Tissue Kit (manufactured by QIAGEN). For the recovered genome, real-time PCR was performed in the same manner as in Experiment 1 above, and in addition to quantifying 16S and CO1 in the plasma of each mouse, CO2, CO3, CYTB, ND1, ND2, ND3, ND4, ND4L, ND5, ND6, ATP6 and ATP8 were also quantified. In addition, in Experiment 3, the abundance of each gene contained in the mitochondrial genome according to the abundance of HK2 was not standardized.

[0058] The base sequences of the forward primer and the reverse primer for CO2 are shown as SEQ ID NO.9 and SEQ ID NO.10, respectively. The base sequences of the forward primer and the reverse primer for CO3 are shown as SEQ ID NO.11 and SEQ ID NO.12, respectively. The base sequences of the forward primer and the reverse primer for CYTB are shown as SEQ ID NO.13 and SEQ ID NO.14, respectively. The base sequences of the forward primer and the reverse primer for ND1 are shown as SEQ ID NO.15 and SEQ ID NO.16, respectively. The base sequences of the forward primer and the reverse primer for ND2 are shown as SEQ ID NO.17 and SEQ ID NO.18, respectively. The base sequences of the forward primer and the reverse primer for ND3 are shown as SEQ ID NO.19 and SEQ ID NO.20, respectively. The base sequences of the forward primer and the reverse primer for ND4 are shown as SEQ ID NO.21 and SEQ ID NO.22, respectively. The base sequences of the forward primer and the reverse primer for ND4L are shown as SEQ ID NO.23 and SEQ ID NO.24, respectively. The base sequences of the forward primer and the reverse primer for ND5 are shown as SEQ ID NO.25 and SEQ ID NO.26, respectively. The base sequences of the forward primer and the reverse primer for ND6 are shown as SEQ ID NO.27 and SEQ ID NO.28, respectively. The base sequences of the forward primer and the reverse primer for ATP6 are shown as SEQ ID NO.29 and SEQ ID NO.30, respectively. The base sequences of the forward primer and the reverse primer for ATP8 are shown as SEQ ID NO.31 and SEQ ID NO.32, respectively.

[0059] (result)

[0060] Figure 3 (A), (B), (C), (D), (E), (F), (G), and (H) show the relative abundance of 16S, CO1, CO2, CYTB, ND1, ND2, ND3, and ATP6 in MeCP2-KO relative to WT, respectively. Figure 4 (A), (B), (C), (D), (E) and (F) show the relative abundance of ATP8, CO3, ND4L, ND4, ND5 and ND6 in MeCP2-KO relative to WT, respectively. The abundance of these genes contained in the mitochondrial genome is higher than that of WT. Table 1 below shows the details of the results of Experiment 3 performed with n=3. In Table 1, "++" indicates an increase of more than 2 times. "+" indicates an increase of more than 1.2 times, but not more than 2 times. "-" indicates that the increase does not reach 1.2 times.

[0061] [Table 1]

[0062]

[0063] The above results show that the expression of most genes in the mitochondrial genome in the plasma of MeCP2-KO mice was higher than that in WT mice. Therefore, it is believed that other genes in the mitochondrial genome also show similar dynamics.

[0064] The above embodiments are used to illustrate the present invention and do not limit the scope of the present invention. That is, the scope of the present invention is represented by the claims rather than the embodiments. In addition, various modifications implemented within the scope of the claims and their equivalent inventions are considered to be within the scope of the present invention.

[0065] This application is based on Japanese Patent Application No. 2022-76396 filed on May 6, 2022. The entire specification, claims and drawings of Japanese Patent Application No. 2022-76396 are incorporated herein by reference.

[0066] Industrial Applicability

[0067] The present invention is applicable to the determination of the pathological state of Rett syndrome.

Claims

1. A kit for determining the pathological state of Rett syndrome, wherein: include: A reagent for detecting a gene contained in the mitochondrial genome in a sample collected from a subject.

2. The Rett syndrome pathological state determination kit according to claim 1, wherein: The reagents are primers for amplifying at least a portion of the base sequence of the gene as a template in a polymerase chain reaction, and a probe hybridizing with at least a portion of the base sequence of an amplification product amplified by the polymerase chain reaction.

3. The Rett syndrome pathological state determination kit according to claim 2, wherein: Also includes: The labeling substance that hybridizes the probe to the base sequence of the amplification product is shown.

4. The Rett syndrome pathological state determination kit according to any one of claims 1 to 3, wherein: The gene is selected from the group consisting of a gene encoding 16S ribosomal RNA, a gene encoding cytochrome c oxidase subunit 1, a gene encoding cytochrome c oxidase subunit 2, a gene encoding cytochrome c oxidase subunit 3, a gene encoding cytochrome b, a gene encoding NADH dehydrogenase 1, a gene encoding NADH dehydrogenase 2, a gene encoding NADH dehydrogenase 3, a gene encoding NADH dehydrogenase 4, a gene encoding NADH dehydrogenase 4L, a gene encoding NADH dehydrogenase 5, a gene encoding NADH dehydrogenase 6, a gene encoding ATP synthase 6, and a gene encoding ATP synthase 8.

5. Use of a gene contained in the mitochondrial genome as a biomarker for assisting in determining the pathological state of Rett syndrome in a subject.